Alpha 2.0
Login Register
» Authors » Pavel Balabanov

Pavel Balabanov

Explore the profile of Pavel Balabanov including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 263
Followers 0
Related Specialties
Pharmacology
Neurology
Psychiatry
Top 10 Co-Authors
Florence Butlen-Ducuing
Manuel Haas
Annemieke Aartsma-Rus
Violeta Stoyanova-Beninska
Marion Haberkamp
Andre Elferink
Eugenio Mercuri
Elizabeth Vroom
Francesco Muntoni
Bruno Sepodes
Published In
Lancet Neurol
Nat Rev Drug Discov
Neuromuscul Disord
Mult Scler
Eur Neuropsychopharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
EU regulatory horizons for Alzheimer's disease
Blanquie O, Guizzaro L, Herold R, Haberkamp M, Elferink A, Balabanov P, et al.
Lancet Neurol . 2025 Jan; 24(2):96-97. PMID: 39862892
No abstract available.
2.
Applying the EU regulatory framework for the clinical use of psychedelics
Butlen-Ducuing F, Silva F, Silva I, Balabanov P, Thirstrup S
Lancet Psychiatry . 2024 Jul; 12(1):7-9. PMID: 38972323
No abstract available.
3.
Methods for Neuroscience Drug Development: Guidance on Standardization of the Process for Defining Clinical Outcome Strategies in Clinical Trials
Zaragoza Domingo S, Alonso J, Ferrer M, Acosta M, Alphs L, Annas P, et al.
Eur Neuropsychopharmacol . 2024 Apr; 83():32-42. PMID: 38579661
Neurosciences clinical trials continue to have notoriously high failure rates. Appropriate outcomes selection in early clinical trials is key to maximizing the likelihood of identifying new treatments in psychiatry and...
4.
The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers
Butlen-Ducuing F, Haberkamp M, Aislaitner G, Balkowiec-Iskra E, Mattila T, Doucet M, et al.
Eur Psychiatry . 2023 Dec; 67(1):e2. PMID: 38098366
According to the World Health Organization (WHO), depressive disorders are currently considered as one of the most disabling medical conditions in the world with one of the highest disability-adjusted life...
5.
The therapeutic potential of psychedelics: the European regulatory perspective
Butlen-Ducuing F, McCulloch D, Haberkamp M, Mattila T, Balkowiec-Iskra E, Aislaitner G, et al.
Lancet . 2023 Feb; 401(10378):714-716. PMID: 36780909
No abstract available.
6.
Implications of sex-related differences in central nervous system disorders for drug research and development
Butlen-Ducuing F, Balkowiec-Iskra E, Dalla C, Slattery D, Ferretti M, Kokras N, et al.
Nat Rev Drug Discov . 2021 Jul; 20(12):881-882. PMID: 34226696
No abstract available.
7.
Digital health technologies in clinical trials for central nervous system drugs: an EU regulatory perspective
Mantua V, Arango C, Balabanov P, Butlen-Ducuing F
Nat Rev Drug Discov . 2020 Sep; 20(2):83-84. PMID: 32994577
No abstract available.
8.
Meeting report of the "Regulatory Exchange Matters" session at the 5th International TREAT-NMD Conference:: Lessons in communication: How an early dialogue between patients, regulators and academics can further therapy development for neuromuscular...
Aartsma-Rus A, Mercuri E, Vroom E, Balabanov P
Neuromuscul Disord . 2018 May; 28(7):619-623. PMID: 29778308
No abstract available.
9.
Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions
Sheean M, Stoyanova-Beninska V, Capovilla G, Duarte D, Hofer M, Hoffmann M, et al.
Drug Discov Today . 2017 Oct; 23(1):26-48. PMID: 28987289
Here, we provide an in-depth literature and experience-based review of nonclinical models and data used to support orphan medicinal product designations (OMPDs) in rare neurodegenerative conditions. The Committee for Orphan...
10.
Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, et al.
Nucleic Acid Ther . 2017 Aug; 27(5):251-259. PMID: 28796573
Duchenne muscular dystrophy (DMD) is a rare, severe, progressive muscle-wasting disease leading to disability and premature death. Patients lack the muscle membrane-stabilizing protein dystrophin. Antisense oligonucleotide (AON)-mediated exon skipping is...